Important Update: GLP-1 Catalog Changes & Your Path Forward
January 1, 2026
Dear Partner,
I wanted to reach out personally with an important update regarding our product catalog — and share where we go from here.
What’s Changing
Effective immediately, GLP-1 receptor agonists are no longer available through YourPeptideBrand.com. This includes Semaglutide, Tirzepatide, and related GLP-1 compounds.
This isn’t just us — this is an industry-wide shift affecting every research peptide supplier. Increased regulatory scrutiny and supply chain changes have made it impossible to continue offering these compounds while maintaining the quality and compliance standards you expect from us.
We know many of you built significant revenue around GLP-1 products. We’re not going to sugarcoat it — this is a transition. But we’ve spent the last several months preparing for this moment, and we’re confident the path forward is even stronger.
Why This Is Actually Good News
Here’s what we’ve learned: the most successful partners in our network weren’t GLP-1 dependent.
They diversified. They educated their customers. They built sustainable businesses around compounds with:
- ✅ Higher profit margins (many 200-400%+ vs. GLP-1’s compressed margins)
- ✅ Less competition (everyone was chasing GLP-1)
- ✅ Stronger customer retention (multi-compound protocols = recurring revenue)
- ✅ Lower regulatory risk (no shortage drama, no gray areas)
The “Beyond GLP-1” Opportunity
Our catalog still includes 60+ research peptides with published research showing distinct mechanisms:
- Cagrilintide (YPB.241) — Amylin pathway, distinct from GLP-1 | 95% margin
- Survodutide (YPB.278) — Dual agonist research | 97% margin
- Tesamorelin (YPB.279) — FDA-approved GHRH analog | 152% margin
- CJC-1295/Ipamorelin Blend (YPB.238) — Gold standard stack | 124% margin
- Ipamorelin (YPB.263) — High volume, high margin | 350% margin
- BPC-157 20mg (YPB.237) — 100+ publications | 413% margin
- Wolverine Blend (YPB.217) — BPC/TB500 combo | 129% margin
- NAD+ 1000mg (YPB.224) — Sirtuin pathway | 300% margin
- GDF-8 (YPB.233) — Myostatin research | 446% margin
- FOXO4-DRI (YPB.255) — Senescence pathway | 178% margin
- Epitalon 10mg (YPB.253) — Telomere research | 406% margin
- PT-141 10mg (YPB.274) — Melanocortin receptor | 356% margin
- NAD+ 500mg (YPB.223) — Entry-level NAD+ | 355% margin
- 5-Amino-1MQ 50mg (YPB.247) — NNMT inhibitor | 207% margin
- MOTS-c 40mg (YPB.271) — Mitochondrial peptide | 206% margin
- GLOW Blend (YPB.218) — GHK-Cu/BPC/TB500 | 267% margin
Your Free Resource: Beyond GLP-1 Guide
We’ve created a comprehensive FDA-compliant research literature guide covering:
- Published research summaries for 25+ compounds
- Mechanism of action comparisons (from peer-reviewed literature)
- Complete wholesale vs. MSRP profit analysis
- Category bundles organized by research pathway
Use this to educate yourself, train your team, and help your customers understand the research landscape beyond GLP-1.
Note: This guide presents published scientific literature for educational purposes. All compounds are for research use only.
What To Do Now
- Download the guide — Get familiar with the alternatives
- Review your inventory — Consider stocking high-margin compounds
- Update your marketing — We can help with compliant messaging
- Talk to your customers — Frame this as an expansion, not a limitation
Need help transitioning? Hit reply — I read every email. Or reach out to our team. We’re here to make sure you come out of this stronger.
The Bottom Line
Yes, GLP-1 is gone. But the partners who thrive will be the ones who see this for what it is: a chance to build a more diversified, higher-margin, lower-risk business.
The research peptide market isn’t shrinking — it’s evolving. And we’re evolving with it.
Let’s build something better together.
Best,
Ben Morgan
CEO, YourPeptideBrand.com
P.S. — Partners who pivot to multi-category offerings typically see higher average order values and better retention. The data is clear: diversification wins.